Radiation therapy

Study Suggests Potential Role for Laser Ablation in Glioblastoma Treatment, Monteris Medical Announces

Retrieved on: 
Tuesday, August 11, 2020
Medicine, Clinical medicine, Medical specialties, Plasma physics, Computer-assisted surgery, Radiation therapy, Laser medicine, Stereotactic surgery, Ablation, Laser, Neurosurgery, Magnetic resonance imaging

To better understand these challenges, the team developed a brain laser therapy system for mice and utilized two different GBM-bearing mouse models.

Key Points: 
  • To better understand these challenges, the team developed a brain laser therapy system for mice and utilized two different GBM-bearing mouse models.
  • Their aim was to understand laser therapy's ability to enable local delivery of small and large molecular size agents through the BBB and BTB over time.
  • Monteris Medical is a privately held company that develops and markets innovative MRI-guided, laser-based systems to perform minimally invasive brain surgery, commonly referred to as "LITT" (Laser Interstitial Thermal Therapy) or "SLA" (Stereotactic Laser Ablation).
  • The Monteris NeuroBlate System is the only minimally invasive system that enables a robotic interface for the precise and safe delivery of laser energy.

American Shared Hospital Services Announces Second Quarter 2020 Earnings Conference Call

Retrieved on: 
Tuesday, August 11, 2020
Health sciences, Health, Natural sciences, Radiobiology, Medical physics, Radiation therapy, Radioactivity, Surgery, New York Stock Exchange, Therapy, AMS

San Francisco, CA, Aug. 11, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American Shared Hospital Services (NYSE American: AMS), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy solutions, today announced that the Company will hold a quarterly conference call to discuss its second quarter 2020 financial results on Friday, August 14, 2020 at 3:00pm EDT / 12:00pm PDT.

Key Points: 
  • San Francisco, CA, Aug. 11, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American Shared Hospital Services (NYSE American: AMS), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy solutions, today announced that the Company will hold a quarterly conference call to discuss its second quarter 2020 financial results on Friday, August 14, 2020 at 3:00pm EDT / 12:00pm PDT.
  • Second quarter 2020 financial results will be released premarket the morning of Friday, August 14, 2020.
  • To participate, please call 1 (800) 774-6070 at least 5 minutes prior to the start of the call and enter passcode number: 7610094#.
  • A replay of the call will be available at the following link through August 28, 2020: https://onlinexperiences.com/Launch/QReg/ShowUUID=941ED238-DFC5-4A86-8B8...
    About American Shared Hospital Services (NYSE American: AMS)
    American Shared Hospital Services provides turnkey technology solutions for advanced radiosurgical and radiation therapy services.

New Research Shows Dose Can be Lowered on NICU Patients without Significantly Impacting Image Quality by Using Samsung Mobile X-Ray System

Retrieved on: 
Monday, August 10, 2020
Medical devices, Other Health, Hospitals, Health, Radiology, Radiobiology, Radiation, Ionizing radiation, Physical sciences, Radiation protection, Radioactivity, Radiography, Radiation therapy, Absorbed dose, Neonatal intensive care unit

Mobile radiography is the most common imaging modality used in NICUs, and the study shows the potential to impact dose levels delivered to neonatal patients.

Key Points: 
  • Mobile radiography is the most common imaging modality used in NICUs, and the study shows the potential to impact dose levels delivered to neonatal patients.
  • This study shows that using the Samsung GM85 with S-Vue, appropriate kVp, mAs, filter and advanced denoising image processing can reduce the radiation dose by up to 36% compared to a conventional system.
  • Technologists are always balancing radiation dose and image quality, so this study has large implications for hospitals and the NICU patients they care for because it shows that its actually possible to achieve a comparable image using a lower-dose protocol.
  • An initial phantom study set-up a dose protocol for the GM85 system that was equivalent to another, conventional mobile DR system.

Radiotherapy Market to Cross $17,194.4 Million Revenue by 2030 Says P&S Intelligence

Retrieved on: 
Thursday, August 6, 2020
Medical physics, Radiation therapy, Radioactivity, Radiobiology, Coronavirus disease, Physical sciences, Health, Natural sciences

Additionally, the American Institute of Cancer Research says that by 2030, around 25 million cases will be diagnosed every year.

Key Points: 
  • Additionally, the American Institute of Cancer Research says that by 2030, around 25 million cases will be diagnosed every year.
  • Due to the coronavirus pandemic, the radiotherapy market is witnessing subdued growth, as the focus of the healthcare fraternity has shifted from chronic diseases to mitigating the COVID-19 spread.
  • The external beam category, on the basis of type, held the largest share in the radiotherapy market in the past.
  • During the next decade, the fastest growth in the radiotherapy market would be witnessed by the hospitals division, under the end-user segment.

TAE Life Sciences to Present at Solebury Trout Summer 2020 Private Company Showcase

Retrieved on: 
Thursday, August 6, 2020
Biotechnology, Other Health, Health, Radiology, Oncology, Physical sciences, Natural sciences, Chemistry, Medical physics, Radiobiology, Nuclear physics, Neutron capture therapy of cancer, Boron, Radiation therapy, Therapy, Neutron

TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions (BNCT), today announced that Bruce Bauer, Chief Executive Officer, will present a corporate overview at the Summer 2020 Private Company Showcase, hosted by Solebury Trout, on August 10, 2020.

Key Points: 
  • TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions (BNCT), today announced that Bruce Bauer, Chief Executive Officer, will present a corporate overview at the Summer 2020 Private Company Showcase, hosted by Solebury Trout, on August 10, 2020.
  • TAE Life Sciences (TLS) is a privately-held biotechnology company committed to developing a new biologically-targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT).
  • TLSs drug and device are currently in development and have not been approved for sale.
  • More information about TAE Life Sciences is available at www.taelifesciences.com
    View source version on businesswire.com: https://www.businesswire.com/news/home/20200806005246/en/

Vyripharm International, Inc. and the National Yang-Ming University Signed a MOU to Develop VYR-206 as a Novel Diagnostic Approach for Neurological Disorders Outcomes Following Treatments

Retrieved on: 
Wednesday, August 5, 2020
Technology, Biotechnology, Health, Radiology, Pharmaceutical, Oncology, University, Other Technology, Mental health, Research, Infectious diseases, Education, Science, Clinical trials, Branches of biology, Medicine, Medical physics, RTT, Medical diagnosis, Medical terminology, Nosology, Neurology, Cancer, Radiation therapy, Health, Vyripharm International, Inc., National Yang-Ming University

The MOU expresses the intent to develop the bio-distribution information and targeting profile of VYR-206 for diagnosis and monitoring treatment outcomes of neurological disorders.

Key Points: 
  • The MOU expresses the intent to develop the bio-distribution information and targeting profile of VYR-206 for diagnosis and monitoring treatment outcomes of neurological disorders.
  • Vyripharms drug platform technology is a personalized medicine application for diagnosis, monitoring and treatment of some infectious diseases, neurological disorders and cancers.
  • Moreover, the platform provides a means for labeling diagnostic and therapeutic agents to allow for tissue specific targeted diagnostic imaging and radiotherapy.
  • We are excited at the prospect of a great collaboration to effectively study these challenging neurological disorders.

Mevion Selected to Provide Proton Therapy System in Córdoba, Spain

Retrieved on: 
Wednesday, August 5, 2020
Oncology, Health, Medical devices, Hospitals, Other Health, Radiology, Biotechnology, Medical physics, Medicine, Physical sciences, Academic disciplines, Radiobiology, Proton, Pencil-beam scanning, Proton therapy, Pencil, Radiation therapy, Therapy

In the initiative, Mevion will provide its revolutionary MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning which will be made available to Andalusian Health Service patients.

Key Points: 
  • In the initiative, Mevion will provide its revolutionary MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning which will be made available to Andalusian Health Service patients.
  • View the full release here: https://www.businesswire.com/news/home/20200805005278/en/
    MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning.
  • To learn more about the proton therapy initiative in Crdoba, Spain, please see the University of Cordoba's announcement .
  • Mevion Medical Systems, Inc. is the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients.

Radiation Business Solutions Continues To Grow National Radiation Oncology Network Through Acquisition Of MBR Medical Billing, Inc.

Retrieved on: 
Tuesday, August 4, 2020
Radiation therapy, Medical physics, Medicine, Radiation oncologist, MBR, Oncology, Physical sciences, Health

NASHVILLE, Tenn., Aug. 4, 2020 /PRNewswire/ --Radiation Business Solutions (RBS) announced that they have reached an agreement to purchase MBR Medical Billing, Inc., a radiation oncology medical billing company with offices in State College, PA and Lewistown, PA, effective July 31, 2020.

Key Points: 
  • NASHVILLE, Tenn., Aug. 4, 2020 /PRNewswire/ --Radiation Business Solutions (RBS) announced that they have reached an agreement to purchase MBR Medical Billing, Inc., a radiation oncology medical billing company with offices in State College, PA and Lewistown, PA, effective July 31, 2020.
  • The MBR acquisition edges us closer to our national goal of 4,000 daily radiation oncology patients with reduced financial toxicity.
  • Radiation Business Solutions, headquartered in Joelton, Tennessee, provides billing, management, de novo center development, and joint venture opportunity to radiation oncologists in both freestanding and hospital centers.
  • With the addition of MBR, RBS now serves nearly 120 physicians at over 60 cancer centers located in 23 states.

Radiation Dose Management Market worth $422.65 million by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, August 3, 2020
Companies, Industries, Medical physics, Business, Radiopharmaceuticals, Radiobiology, Amersham, GE Healthcare, Magnetic resonance imaging, Bayer, Radiation therapy, General Electric

The oncology segment accounted for the largest market share in 2019.

Key Points: 
  • The oncology segment accounted for the largest market share in 2019.
  • This has resulted in the rising adoption of imaging techniques for cancer detection and treatment planning, thus driving the demand for radiation dose management software as well.
  • Based on end users, the market is segmented into hospitals, ambulatory care settings, and other end users.
  • The major players in the Radiation Dose Management Market are Bayer AG (Germany), GE Healthcare (US), PACSHealth, LLC (US), and Sectra Medical Systems (Sweden).

Radiation Dose Management Market worth $422.65 million by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, August 3, 2020
Companies, Industries, Medical physics, Business, Radiopharmaceuticals, Radiobiology, Amersham, GE Healthcare, Magnetic resonance imaging, Bayer, Radiation therapy, General Electric

The oncology segment accounted for the largest market share in 2019.

Key Points: 
  • The oncology segment accounted for the largest market share in 2019.
  • This has resulted in the rising adoption of imaging techniques for cancer detection and treatment planning, thus driving the demand for radiation dose management software as well.
  • Based on end users, the market is segmented into hospitals, ambulatory care settings, and other end users.
  • The major players in the Radiation Dose Management Market are Bayer AG (Germany), GE Healthcare (US), PACSHealth, LLC (US), and Sectra Medical Systems (Sweden).